OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (OPEN-IT)

Carlos Roberto Simons-Linares

Status and phase: Enrolling; Phase 4

Conditions: Marginal Ulcer

Treatments: Drug: Omeprazole 40 milligrams

Study type: Interventional

Funder types: Other

Identifiers

NCT05799105

23-024

Details and patient eligibility

About

The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery. The main questions it aims to answer are:

• is taking an acid-blocking medication by opening the capsule and only taking the contents of the capsule (open-capsule) more or less effective than taking the capsule as a whole (intact-capsule) for treating ulcers in patients who have a history of gastric bypass surgery?
• does taking the open versus intact medication decrease the number of procedures and complications from untreated ulcers?

Participants with ulcers will be instructed to take acid-blocking medications (called proton-pump inhibitors) either by opening the capsule and taking only the contents or by taking the capsule whole. These medications are the gold standard for treatment of stomach ulcers. Participants will be asked to undergo an upper endoscopy (EGD) every 3 months to monitor the healing of the ulcers.

Researchers will compare how quickly the ulcers heal depending on which way the medications are taken (opened up or as a whole).

Full description

Marginal ulcers (ulcers formed at the surgery site between the stomach and the intestines) are a common complication of bariatric surgery, ranging in frequency from 0.6-25% of patients. Furthermore, roughly 17% of patients with marginal ulcers require repeat procedures or surgery for severe complications such as bleeding, perforation, stricture, and fistulas.

Proton pump inhibitors (PPIs), which act by block acid secretion from the stomach, are the gold standard for treatment of ulcers. There is limited data showing that opening the PPI capsule and taking only the contents greatly improves healing of marginal ulcers after gastric bypass surgery. This is likely due to the much smaller stomach, faster passage through the stomach and decreased ability of the intact PPI medication to be broken down and absorbed.

This would be the first clinical trial to confirm whether this is true, which would support all patients who get ulcers after gastric bypass surgery to be treated with open-capsule PPI medications.

Enrollment: 122 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects diagnosed with marginal ulceration post-gastric bypass on upper endoscopy

Exclusion criteria

• Refusal to start PPI medication OR current open-capsule PPI use at the time of diagnosis of the marginal ulcer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

122 participants in 2 patient groups

Open-capsule

Experimental group

Description:

Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an open-capsule until confirmed ulcer healing.

Treatment:

Drug: Omeprazole 40 milligrams

Intact-capsule

Active Comparator group

Description:

Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an intact-capsule until confirmed ulcer healing or potential cross-over.

Treatment:

Drug: Omeprazole 40 milligrams